Mr. Brazzale is the Founder, President, and CEO of Gordian Biotechnologies. He was previously co-founder and Vice President of Product and Business Development for Melanovus Oncology, a life science company developing therapeutics for the treatment of metastatic melanoma. A successful exit for Melanovus closed with the sale of the company to Cipher Pharmaceuticals. He began his career at Abbott Laboratories in 1996 as a research scientist in the area of antibiotic drug discovery leading to an eventual clinical phase III candidate, Cethromycin. In 1999 he was recruited by Wyeth to continue his drug development career in the area of woman’s health. He is an inventor on numerous patents and an author of multiple published peer-reviewed journal articles. He left the lab in 2003 to pursue operations, sales, and business development positions in the life sciences with companies including Biotage, Argonaut Technologies, and BIA Separations, where he spent three years as the Vice President of Business Development for North America and special advisor to the Board of Directors.
In 2011 Tony founded Biotech Business Development, Inc., a corporate strategy and finance advisory focused on the global life sciences industry. The company’s mission is to add and create value for therapeutic and technology-based companies by implementing operational improvements and business development strategies.
Tony is a member of a number of scientific and professional societies including the Licensing Executives Society and the American Chemical Society (ACS), where he will began a three-year chair succession in 2012 in the Division of Business Development and Management. He is also an advisor to the Entrepreneurial Resource Center, part of the Entrepreneurial Initiative within the ACS.
Tony earned a Bachelor of Science degree in chemistry from Southern Illinois University in 1996 and also competed as a NCAA Division I swimmer for the Salukis.
Mr. Goldstein has distinguished himself with more than 30 years of experience in commercializing life sciences technologies. He has been responsible for building and directing marketing, engineering and sales teams that have created more than 10 key product categories in the research marketplace.
He began his career with LKB Instruments and later held senior level positions directing marketing, sales and customer service for Amnis Corporation, Molecular Devices Corporation, Molecular Dynamics, Inc., and Applied Biosystems, Inc. Mr. Goldstein was founder, president and CEO of the eBioinformatics unit of Entigen Corporation, senior vice president at Incyte Genomics, where he oversaw global sales and marketing of all Incyte’s products and services, and senior vice president at Synteni Corporation, which was acquired by Incyte. He served as CEO and Chief Commercial Officer for Arcxis Biotechnologies as well as Managing Partner of Practical Marketing & Sales, a marketing and sales consultation company. Most recently Mr. Goldstein was Executive Vice President of IntegenX Inc. where he was responsible for the re-positioning of the company’s flagship products as well as building a worldwide distribution organization. He is currently the Head of Strategic Initiatives at GenapSys, a company developing a disruptive DNA-sequencing technology based on our simple label-free proprietary technology, enabling fast, accurate, and low cost genetic testing.
Mr. Goldstein received his MBA in Organizational Development from Temple University in Philadelphia, and completed graduate school in Biochemistry from University of Dayton in Ohio after receiving his undergraduate degree in Biology from Bucknell University in Pennsylvania.
Mr. Kim is CEO and Chairman of DHK Pharma, Inc., which he founded in 2007. He has over 25 years’ experience in global pharmaceutical commercialization. Mr. Kim’s therapeutic experience includes infectious diseases, oncology, and hospital medical devices ranging from wound care to aesthetic products. He also led development teams in healthcare information technology (IT). In his career, he worked with senior executives and scientists at Roche, Pfizer, and Novartis, developing a unique strategic approach to a therapeutic franchise development with over $1B in investment. He has led commercial and scientific teams in over a dozen due-diligence efforts, from new product acquisition to life-cycle management.
Mr. Kim formerly was President and Publisher of Elsevier Oncology from 2008 to 2011, overseeing their oncology medical journals and international medical and nursing education conferences in cancer management. Prior to 2008, he held positions of increasing responsibilities in marketing and product development at Roche, Pfizer, and Novartis Pharmaceuticals